Chris Twelves

Summary

Affiliation: University of Leeds
Country: UK

Publications

  1. doi request reprint Trials and tribulations of cytotoxic and targeted breast cancer therapy: a clinical perspective on the next phase of progress. Interview by Sophia Maprayil and Alexandra Hemsley
    Chris Twelves
    Level 4, Bexley Wing, St James s University Hospital, Beckett Street, Leeds, LS9 7TF, UK
    Expert Rev Anticancer Ther 13:251-5. 2013
  2. pmc Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses
    D Alan Anthoney
    St James Institute of Oncology, University of Leeds and Leeds Teaching Hospitals Trust, Leeds LS9 7TF, United Kingdom
    BMC Cancer 12:536. 2012
  3. doi request reprint Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy
    C Twelves
    University of Leeds and St James s Institute of Oncology Hospital, Leeds Cancer Research UK Centre, Leeds, UK
    Ann Oncol 23:1190-7. 2012
  4. doi request reprint Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer
    Chris Twelves
    Leeds Institute of Molecular Medicine, St James University Hospital, Leeds, United Kingdom
    Clin Breast Cancer 10:160-3. 2010
  5. doi request reprint Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
    Javier Cortes
    Vall d Hebron University Hospital, Vall d Hebron Institute of Oncology, Barcelona, Spain
    Lancet 377:914-23. 2011
  6. doi request reprint Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study
    Chris Twelves
    University of Leeds and St James Hospital, Leeds, United Kingdom
    Eur J Cancer 44:419-26. 2008
  7. ncbi request reprint Is oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin an option for stage II and III colon cancer?
    Chris Twelves
    Cancer Research UK Clinical Centre, University of Leeds, UK
    Nat Clin Pract Oncol 5:72-3. 2008
  8. doi request reprint Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine
    Javier Cortes
    Vall d Hebron University Hospital, Barcelona, Spain
    J Clin Oncol 28:3922-8. 2010
  9. ncbi request reprint Capecitabine as adjuvant treatment for stage III colon cancer
    Chris Twelves
    University of Leeds and Bradford NHS Hospitals Trust, Leeds, United Kingdom
    N Engl J Med 352:2696-704. 2005
  10. pmc Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer
    Hyman Muss
    University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA Vall d Hebron University Hospital and Vall d Hebron Institute of Oncology, Barcelona, Spain Weill Cornell Medical College, New York, New York, USA Jules Bordet Institute, Brussels, Belgium University of Leeds and St James s Institute of Oncology, Leeds, UK Formerly of Eisai Ltd, Hatfield, UK Eisai Inc, Woodcliff Lake, New Jersey, USA NJS Associates Company, Somerset, New Jersey USA Baylor Charles A Sammons Cancer Center, Texas Oncology, and US Oncology, Dallas, Texas, USA
    Oncologist 19:318-27. 2014

Detail Information

Publications35

  1. doi request reprint Trials and tribulations of cytotoxic and targeted breast cancer therapy: a clinical perspective on the next phase of progress. Interview by Sophia Maprayil and Alexandra Hemsley
    Chris Twelves
    Level 4, Bexley Wing, St James s University Hospital, Beckett Street, Leeds, LS9 7TF, UK
    Expert Rev Anticancer Ther 13:251-5. 2013
    Interview by Sophia Maprayil and Alexandra Hemsley, Commissioning Editors Chris Twelves is a medical oncologist and leads the Section of Oncology and Clinical Research at Cancer Research UK's Clinical Centre at St James's Hospital, Leeds...
  2. pmc Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses
    D Alan Anthoney
    St James Institute of Oncology, University of Leeds and Leeds Teaching Hospitals Trust, Leeds LS9 7TF, United Kingdom
    BMC Cancer 12:536. 2012
    ..A Phase I dose escalation first in man study assessed maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and recommended Phase II dose of TP300, a water soluble prodrug of the Topo-1 inhibitor TP3076, and active metabolite, TP3011...
  3. doi request reprint Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy
    C Twelves
    University of Leeds and St James s Institute of Oncology Hospital, Leeds Cancer Research UK Centre, Leeds, UK
    Ann Oncol 23:1190-7. 2012
    ..This multicenter randomized trial compared oral capecitabine with bolus i.v. 5-fluorouracil (5-FU)/folinic acid (FA) as adjuvant therapy for stage III colon cancer...
  4. doi request reprint Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer
    Chris Twelves
    Leeds Institute of Molecular Medicine, St James University Hospital, Leeds, United Kingdom
    Clin Breast Cancer 10:160-3. 2010
    ..Tumor assessments are carried out every 8 weeks in Study 305, and every 2 cycles (each of 3 weeks' duration) in Study 301. Safety is also assessed in both studies...
  5. doi request reprint Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
    Javier Cortes
    Vall d Hebron University Hospital, Vall d Hebron Institute of Oncology, Barcelona, Spain
    Lancet 377:914-23. 2011
    ..Eribulin mesilate is a non-taxane microtubule dynamics inhibitor with a novel mode of action. We aimed to compare overall survival of heavily pretreated patients receiving eribulin versus currently available treatments...
  6. doi request reprint Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study
    Chris Twelves
    University of Leeds and St James Hospital, Leeds, United Kingdom
    Eur J Cancer 44:419-26. 2008
    ..Pharmacokinetic studies showed that exposure to the three drugs was not reduced when given in combination. These encouraging preliminary results warrant further trials of the combination in MBC...
  7. ncbi request reprint Is oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin an option for stage II and III colon cancer?
    Chris Twelves
    Cancer Research UK Clinical Centre, University of Leeds, UK
    Nat Clin Pract Oncol 5:72-3. 2008
  8. doi request reprint Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine
    Javier Cortes
    Vall d Hebron University Hospital, Barcelona, Spain
    J Clin Oncol 28:3922-8. 2010
    ....
  9. ncbi request reprint Capecitabine as adjuvant treatment for stage III colon cancer
    Chris Twelves
    University of Leeds and Bradford NHS Hospitals Trust, Leeds, United Kingdom
    N Engl J Med 352:2696-704. 2005
    ..The oral fluoropyrimidine capecitabine is an established alternative to bolus fluorouracil plus leucovorin as first-line treatment for metastatic colorectal cancer. We evaluated capecitabine in the adjuvant setting...
  10. pmc Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer
    Hyman Muss
    University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA Vall d Hebron University Hospital and Vall d Hebron Institute of Oncology, Barcelona, Spain Weill Cornell Medical College, New York, New York, USA Jules Bordet Institute, Brussels, Belgium University of Leeds and St James s Institute of Oncology, Leeds, UK Formerly of Eisai Ltd, Hatfield, UK Eisai Inc, Woodcliff Lake, New Jersey, USA NJS Associates Company, Somerset, New Jersey USA Baylor Charles A Sammons Cancer Center, Texas Oncology, and US Oncology, Dallas, Texas, USA
    Oncologist 19:318-27. 2014
    ..Following the demonstrated efficacy and safety of eribulin mesylate in heavily pretreated patients with metastatic breast cancer, an exploratory analysis was performed to investigate the effect of age in these patients...
  11. pmc Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database
    Qian Shi
    Qian Shi, Axel Grothey, Brian M Bot, and Daniel J Sargent, North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN Thierry Andre, Hopital Saint Antoine, Paris, France Greg Yothers and Michael J O Connell, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh Daniel G Haller, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA Stanley R Hamilton, University of Texas MD Anderson Cancer Center, Houston, TX Brian M Bot, Sage Bionetworks Jacqueline K Benedetti, Southwest Oncology Group Statistical Center, Seattle, WA Eric Van Cutsem, University Hospital Gasthuisberg, Gasthuisberg, Belgium and Chris Twelves, St James s University Hospital, Leeds, United Kingdom
    J Clin Oncol 31:3656-63. 2013
    ....
  12. ncbi request reprint Scheduling of taxanes: a review
    Emma J Woodward
    St James s Institute of Oncology, Leeds, UK
    Curr Clin Pharmacol 5:226-31. 2010
    ..In practice, the choice of schedule is a balance between the better tolerability (and possibly efficacy) of weekly treatment balanced against the inconvenience for both the patient and clinic of more frequent visits for chemotherapy...
  13. doi request reprint Tubulin: an example of targeted chemotherapy
    Jenny Seligmann
    Section of Oncology and Clinical Research, Leeds Institute of Molecular Medicine, St James Institute of Oncology, St James University Hospital, Leeds, UK
    Future Med Chem 5:339-52. 2013
    ..Agents demonstrating utility in Phase III clinical trials, including eribulin, ixabepilone, cabazitaxel and trastuzumab-DM1 will be highlighted, as well as novel agents currently in development and future directions for MTAs...
  14. doi request reprint Loading doses for costly cancer biologicals: a cause for concern or tilting at windmills?
    Ivo M Hennig
    Section of Oncology and Clinical Research, Cancer Research UK Clinical Centre, Leeds Institute of Molecular Medicine, University of Leeds and St James s University Hospital, 4th Floor, Bexley Wing, Leeds LS9 7TF, UK
    Eur J Cancer 44:1493-6. 2008
    ..Rather, the issue of loading doses should be seen in the broader context of how best to define the optimal dose, schedule and duration of treatment through novel clinical trial designs...
  15. doi request reprint Clinical grade OK432-activated dendritic cells: in vitro characterization and tracking during intralymphatic delivery
    Emma West
    Cancer Research UK Clinical Centre, Leeds Institute of Molecular Medicine, Leeds Teaching Hospitals NHS Trust, St James s University Hospital Leeds, UK
    J Immunother 32:66-78. 2009
    ..These results show that OK-DC are suitable for clinical use, and that intralymphatic delivery is feasible for localizing cells to sites where optimal priming of innate and adaptive antitumor immunity is likely to occur...
  16. doi request reprint Potential regional differences for the tolerability profiles of fluoropyrimidines
    Daniel G Haller
    Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 26:2118-23. 2008
    ....
  17. ncbi request reprint Docetaxel weekly with metastatic breast cancer
    Chris Twelves
    Onkologie 30:407-8. 2007
  18. ncbi request reprint Treatment for anthracycline-pretreated metastatic breast cancer
    Joyce O'Shaughnessy
    Baylor Sammons Cancer Center and US Oncology, Dallas, Texas 75246, USA
    Oncologist 7:4-12. 2002
    ....
  19. ncbi request reprint XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer
    Jim Cassidy
    CRC Department of Oncology, University of Glasgow, Garscube Estate, Bearsden, Glasgow G61 1DB, United Kingdom
    J Clin Oncol 22:2084-91. 2004
    ..The present studies further characterize efficacy and safety of the XELOX regimen...
  20. ncbi request reprint Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results
    Joyce O'Shaughnessy
    Baylor Sammons Cancer Center, Dallas, TX 75246, USA
    J Clin Oncol 20:2812-23. 2002
    ..This international phase III trial compared efficacy and tolerability of capecitabine/docetaxel therapy with single-agent docetaxel in anthracycline-pretreated patients with MBC...
  21. ncbi request reprint Moving forward with capecitabine: a glimpse of the future
    Laura Biganzoli
    EORTC Investigational Drug Branch for Breast Cancer, Chemotherapy Unit, Institut Jules Bordet, Brussels, Belgium
    Oncologist 7:29-35. 2002
    ..Confirmatory studies for many of these combinations and phase III trials versus standard therapy are now warranted...
  22. ncbi request reprint Capecitabine plus docetaxel combination therapy
    Shailendra Verma
    Department of Medical Oncology, Ottawa Regional Cancer Centre, Ottawa, Canada
    Cancer 103:2455-65. 2005
    ..The current study evaluated the cost-effectiveness of the capecitabine/docetaxel combination versus docetaxel monotherapy, comparing the gain in quality-adjusted survival with associated health care costs...
  23. ncbi request reprint Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda)
    Robert Leonard
    South Wales Cancer Institute, Swansea, UK
    Semin Oncol 31:21-8. 2004
    ..In summary, the treatment of MBC will always need to be individualized, but a large body of evidence indicates that capecitabine, whether alone or in combination, can be offered to women early in the disease course...
  24. pmc Assessment of the validity of a population pharmacokinetic model for epirubicin
    Lorraine D Ralph
    Division of Cardiovascular and Medical Sciences, University of Glasgow, Western Infirmary, Glasgow, UK
    Br J Clin Pharmacol 62:47-55. 2006
    ..The aim of this study was to evaluate a population model for epirubicin clearance using internal and external validation techniques...
  25. ncbi request reprint Capecitabine (Xeloda): from the laboratory to the patient's home
    George Pentheroudakis
    Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, Scotland, UK
    Clin Colorectal Cancer 2:16-23. 2002
    ..As a home-based outpatient regimen, capecitabine represents a safe and effective advance in modern drug development...
  26. ncbi request reprint Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study
    Charlotte Van Kesteren
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Amsterdam, The Netherlands
    Anticancer Drugs 13:381-93. 2002
    ..Administration of 1650 microg/m(2) ET-743 over 3 h seemed clinically feasible; pharmacokinetics were linear with this schedule. Hepatic and hematological toxicities correlated with exposure to ET-743...
  27. ncbi request reprint A population model of epirubicin pharmacokinetics and application to dosage guidelines
    Lorraine D Ralph
    Clinical Pharmacology Section, Division of Cardiovascular and Medical Sciences, University of Glasgow, North Glasgow University Hospitals NHS Trust, Glasgow, UK
    Cancer Chemother Pharmacol 52:34-40. 2003
    ..To use a population approach to identify readily available clinical or biochemical characteristics that influence the pharmacokinetics of epirubicin and to develop new dosage guidelines based on these results...
  28. ncbi request reprint A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies
    Chris Twelves
    Cancer Research UK Department of Medical Oncology, Beatson Laboratories, University of Glasgow, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK
    Cancer Chemother Pharmacol 52:277-81. 2003
    ..The aim of this open-label phase I study was to determine the maximum tolerated dose (MTD), safety, and antitumour activity of ZD0473 followed by paclitaxel in patients with refractory solid malignancies...
  29. ncbi request reprint Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors
    Hans Gelderblom
    Department of Medical Oncology, Erasmus MC Daniel den Hoed, 3008 AE Rotterdam, The Netherlands
    Clin Cancer Res 9:4101-7. 2003
    ..This Phase I study was performed to assess the feasibility of the administration of oral diflomotecan, to determine the maximum-tolerated, dose its bioavailability, and to explore the pharmacokinetics...
  30. ncbi request reprint Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Re
    Andrew Bottomley
    Quality of Life Unit, European Organization for Research and Treatment of Cancer Data Center, Insitut Jules Bordet, Brussels, Belgium
    J Clin Oncol 22:2576-86. 2004
    ..To compare health-related quality of life (HRQOL) in patients with metastatic breast cancer receiving the combination of doxorubicin and paclitaxel (AT) or doxorubicin and cyclophosphamide (AC) as first-line chemotherapy treatment...
  31. ncbi request reprint Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study
    Alain Ravaud
    Department of Medicine, Institut Bergonie, Bordeaux, France
    Eur J Cancer 41:702-7. 2005
    ..The pharmacokinetics of CHS 828 showed large variations both between and within patients. No objective responses were seen. A dose of 420 mg of CHS 828 administered every 3 weeks is the recommended dose, while 500 mg is the MTD...
  32. ncbi request reprint Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors
    Gernot Beutel
    Department of Hematology, Hemostaseology and Oncology, Hannover Medical School, Hannover, Germany
    Clin Cancer Res 11:5487-95. 2005
    ..This phase I study was done to establish the safety, tolerability, maximum tolerated dose, recommended dose, and pharmacokinetics of OSI-7904L in patients with advanced solid tumors refractory to standard therapy...
  33. ncbi request reprint Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG
    Markus Joerger
    Department of Pharmacy and Pharmacology, Netherlands Cancer Institute Slotervaart Hospital, Amsterdam, The Netherlands
    Clin Pharmacokinet 46:1051-68. 2007
    ..To investigate the population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients...
  34. ncbi request reprint Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors
    Kim Appleton
    Centre for Oncology and Applied Pharmacology, Glasgow University, Cancer Research UK Beatson Laboratories, Glasgow, United Kingdom
    J Clin Oncol 25:4603-9. 2007
    ..We designed a clinical study to determine the feasibility of delivering a dose of decitabine, combined with carboplatin, that would be capable of producing equivalent biologic effects in patients with solid tumors...
  35. ncbi request reprint Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients
    Christopher Poole
    CRC Institute for Cancer Research, University of Birmingham, Birmingham, UK
    Cancer Chemother Pharmacol 49:225-34. 2002
    ..Capecitabine (Xeloda) is an orally administered precursor of 5'-deoxy-5-fluorouridine (5'-DFUR), which is preferentially activated to 5-fluorouracil (5-FU) in tumors...